Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) ...(uation (FAME) study will be announced in...)

Date:9/21/2009

uation (FAME) study will be announced in the main arena at TCT. The one-year FAME study results, originally presented at TCT 2008 and published in the New England Journal of Medicine, demonstrated that patients with multi-vessel coronary artery disease who were treated with FFR guidance had a significant reduction in major adverse coronary events (MACE) compared to angiographic guidance alone. Not only were these improvements seen clinically, but there was also a reduction in the total procedural cost in the FFR-guided group. At TCT, the 2-year FAME data will be presented to examine the sustained benefits of FFR guidance over a longer period of time, in addition to specific patient demographic subsets. Patient safety, better outcomes and lower costs are central topics in healthcare reform and FFR is an easy-to-use, accessible tool that is available in most hospitals world wide.

Following the FAME announcement, the first follow-up results of the much anticipated PROSPECT trial (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) will be presented on Thursday, September 24 at 12:15 PM in the main arena at TCT. PROSPECT is the first multicenter natural history study using Volcano's grayscale IVUS and proprietary VH IVUS technology, designed to examine which lesions progress rapidly in patients, and which lesions remain stable for years to come. Data has been collected for more than three years on these patients, and the event data will be presented for the very first time at TCT. Detailed results of the study will also be the focus of the first session of Volcano's symposium that evening. Gregg W. Stone, M.D., Principle Investigator of PROSPECT, will discuss how plaque characterization can help predict future coronary events at the symposium.

"Despite years of effort, researchers using the traditional angiogram have had great difficulty predicting which lesions will progress versus which wi
'/>"/>

SOURCE Volcano Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
2. Volcano Corporation Announces Pricing of Common Stock Offering
3. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
4. Volcano Announces Closing of CardioSpectra Acquisition
5. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
6. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
7. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
8. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
11. Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System